Arbutus Biopharma Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -58.71 M

Arbutus Biopharma Corporation Operating Cash Flow is USD -58.71 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -23.62% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Arbutus Biopharma Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -76.86 M, a -7.70% change year over year.
  • Arbutus Biopharma Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -83.28 M, a 186.84% change year over year.
  • Arbutus Biopharma Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -29.03 M, a -46.11% change year over year.
  • Arbutus Biopharma Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -53.87 M, a -22.91% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities